Nanomedicine for uterine leiomyoma therapy

Research output: Contribution to journalArticle

12 Citations (Scopus)

Abstract

Background: The purpose of this work was to engineer polymeric nanoparticles to encapsulate and deliver 2-methoxyestradiol, a potential antitumor drug for treatment of uterine leiomyoma (fibroids), the most common hormone-dependent pathology affecting women of reproductive age. Methods/Results: Encapsulation efficiency and drug release from the nanoparticles were monitored by HPLC. Cell morphology and in vitro cytotoxicity experiments were carried out in a human leiomyoma cell line. The nanoparticles displayed high encapsulation efficiency (>86%), which was verified by differential scanning calorimetry and X-ray diffraction. Excellent long-term stability of the nanoparticles and gradual drug release without burst were also observed. Cellular uptake of fluorescent nanoparticles was confirmed by confocal imaging. The drug-loaded poly(lactic acid) and poly(lactic-co-glycolic acid) nanoparticles induced cytotoxicity in human leiomyoma cells to a significantly greater extent than the free drug at 0.35 M. Conclusion: This novel approach represents a potential fertility-preserving alternative to hysterectomy.

Original languageEnglish (US)
Pages (from-to)161-175
Number of pages15
JournalTherapeutic Delivery
Volume4
Issue number2
DOIs
StatePublished - Feb 2013

Fingerprint

Nanomedicine
Leiomyoma
Nanoparticles
Therapeutics
Differential Scanning Calorimetry
Hysterectomy
X-Ray Diffraction
Pharmaceutical Preparations
Antineoplastic Agents
Fertility
High Pressure Liquid Chromatography
Hormones
Pathology
Cell Line

ASJC Scopus subject areas

  • Pharmaceutical Science

Cite this

Nanomedicine for uterine leiomyoma therapy. / Ali, Hazem; Kilic, Gokhan; Vincent, Kathleen; Motamedi, Massoud; Rytting, Erik.

In: Therapeutic Delivery, Vol. 4, No. 2, 02.2013, p. 161-175.

Research output: Contribution to journalArticle

@article{05c4c10c3f7f45729e449485237c3c81,
title = "Nanomedicine for uterine leiomyoma therapy",
abstract = "Background: The purpose of this work was to engineer polymeric nanoparticles to encapsulate and deliver 2-methoxyestradiol, a potential antitumor drug for treatment of uterine leiomyoma (fibroids), the most common hormone-dependent pathology affecting women of reproductive age. Methods/Results: Encapsulation efficiency and drug release from the nanoparticles were monitored by HPLC. Cell morphology and in vitro cytotoxicity experiments were carried out in a human leiomyoma cell line. The nanoparticles displayed high encapsulation efficiency (>86{\%}), which was verified by differential scanning calorimetry and X-ray diffraction. Excellent long-term stability of the nanoparticles and gradual drug release without burst were also observed. Cellular uptake of fluorescent nanoparticles was confirmed by confocal imaging. The drug-loaded poly(lactic acid) and poly(lactic-co-glycolic acid) nanoparticles induced cytotoxicity in human leiomyoma cells to a significantly greater extent than the free drug at 0.35 M. Conclusion: This novel approach represents a potential fertility-preserving alternative to hysterectomy.",
author = "Hazem Ali and Gokhan Kilic and Kathleen Vincent and Massoud Motamedi and Erik Rytting",
year = "2013",
month = "2",
doi = "10.4155/tde.12.144",
language = "English (US)",
volume = "4",
pages = "161--175",
journal = "Therapeutic Delivery",
issn = "2041-5990",
publisher = "Future Science",
number = "2",

}

TY - JOUR

T1 - Nanomedicine for uterine leiomyoma therapy

AU - Ali, Hazem

AU - Kilic, Gokhan

AU - Vincent, Kathleen

AU - Motamedi, Massoud

AU - Rytting, Erik

PY - 2013/2

Y1 - 2013/2

N2 - Background: The purpose of this work was to engineer polymeric nanoparticles to encapsulate and deliver 2-methoxyestradiol, a potential antitumor drug for treatment of uterine leiomyoma (fibroids), the most common hormone-dependent pathology affecting women of reproductive age. Methods/Results: Encapsulation efficiency and drug release from the nanoparticles were monitored by HPLC. Cell morphology and in vitro cytotoxicity experiments were carried out in a human leiomyoma cell line. The nanoparticles displayed high encapsulation efficiency (>86%), which was verified by differential scanning calorimetry and X-ray diffraction. Excellent long-term stability of the nanoparticles and gradual drug release without burst were also observed. Cellular uptake of fluorescent nanoparticles was confirmed by confocal imaging. The drug-loaded poly(lactic acid) and poly(lactic-co-glycolic acid) nanoparticles induced cytotoxicity in human leiomyoma cells to a significantly greater extent than the free drug at 0.35 M. Conclusion: This novel approach represents a potential fertility-preserving alternative to hysterectomy.

AB - Background: The purpose of this work was to engineer polymeric nanoparticles to encapsulate and deliver 2-methoxyestradiol, a potential antitumor drug for treatment of uterine leiomyoma (fibroids), the most common hormone-dependent pathology affecting women of reproductive age. Methods/Results: Encapsulation efficiency and drug release from the nanoparticles were monitored by HPLC. Cell morphology and in vitro cytotoxicity experiments were carried out in a human leiomyoma cell line. The nanoparticles displayed high encapsulation efficiency (>86%), which was verified by differential scanning calorimetry and X-ray diffraction. Excellent long-term stability of the nanoparticles and gradual drug release without burst were also observed. Cellular uptake of fluorescent nanoparticles was confirmed by confocal imaging. The drug-loaded poly(lactic acid) and poly(lactic-co-glycolic acid) nanoparticles induced cytotoxicity in human leiomyoma cells to a significantly greater extent than the free drug at 0.35 M. Conclusion: This novel approach represents a potential fertility-preserving alternative to hysterectomy.

UR - http://www.scopus.com/inward/record.url?scp=84872943729&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84872943729&partnerID=8YFLogxK

U2 - 10.4155/tde.12.144

DO - 10.4155/tde.12.144

M3 - Article

VL - 4

SP - 161

EP - 175

JO - Therapeutic Delivery

JF - Therapeutic Delivery

SN - 2041-5990

IS - 2

ER -